Kingmed Diagnostics
Kingmed Diagnostics
Kingmed Diagnostics is a third-party medical inspection service provider.
Kingmed Diagnostics, established in 1994, is a third-party medical inspection and pathological diagnosis service provider, mainly engaging in third-party medical assessment and pathological diagnosis business and providing leading medical diagnosis information integration services and and pathological diagnosis outsourcing services for medical institutions at all levels across the country. Founded by Guangzhou Medical University, it went public in September 2017. Its main shareholder is Liang Yaoming, and peer companies are Transtek Medical Electronics and Inkon Life Technology.
- All
- News
- Analysis
- Research
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
In-depth
Healthcare
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Healthcare
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Briefing Jan 12, 2022 12:18 PM
· Healthcare
Jinyu medicine: we are actively cooperating in the investigation of Jinyu incident in Zhengzhou
Briefing Nov 17, 2021 06:02 PM
Gilid signed an agreement with science and technology to deepen strategic cooperation in the areas of chronic hepatitis B, hepatitis C and HIV infection.
Briefing Jul 29, 2021 10:01 AM
Back to Hong Kong, Chinese concept stocks rose collectively, and Wanguo data rose 17.5%
See more
Related Companies
